Gláucia Maria Moraes de Oliveira

A Estatística Cardiovascular – Brasil foi estabelecida para fornecer avaliação da saúde cardiovascular no Brasil de maneira periódica, abrangente e baseada em evidência, assim como para apoiar a prática clínica, a pesquisa, o planejamento em saúde pública e a elaboração de políticas.1-3 Desenvolvida sob os auspícios da Sociedade Brasileira de Cardiologia, a iniciativa reúne uma rede multidisciplinar de investigadores de instituições acadêmicas em todo o país, que são responsáveis pela revisão, análise e interpretação dos dados de múltiplas fontes complementares. [...] A Estatística Cardiovascular – Brasil foi estabelecida para fornecer avaliação da saúde cardiovascular no Brasil de maneira periódica, abrangente e baseada em evidência, assim como para apoiar a prática clínica, a pesquisa, o planejamento em saúde pública e a elaboração de políticas.1-3 Desenvolvida sob os auspícios da Sociedade Brasileira de Cardiologia, a iniciativa reúne uma rede multidisciplinar de investigadores de instituições acadêmicas em todo o país, que são responsáveis pela revisão, análise e interpretação dos dados de múltiplas fontes complementares.

Extending women’s health-span is a key challenge for the medical community. Although women live longer than men, they face a higher burden of chronic diseases, such as cardiovascular diseases (CVDs) and disabilities. Endogenous estrogens appear to benefit cardiovascular health, and their marked decline at menopause is associated with increased cardiovascular risk; conversely, poor cardiovascular health may hasten menopause onset. Systemic menopause hormone therapy (MHT) begun early—ideally soon after symptom onset and at most within 10 years of the final menstrual period—alleviates climacteric symptoms and is associated with long-term benefits. This joint position paper between the International Federation of Gynecology and Obstetrics (FIGO) and the World Heart Federation (WHF) aims at supporting both gynecologists and cardiologists in providing a tailored and evidence-based counseling on systemic MHT use to women with increased CVD risk or established ischemic heart disease (IHD). Women with CVD risk factors require thorough risk stratification to tailor MHT type, dose, and route. For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. Women with established IHD may receive systemic MHT for symptom relief, provided risks and benefits are carefully reviewed. Transdermal low-dose estrogen, alone or with micronized progesterone or dydrogesterone, is the best choice. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care.

Extending women's health‐span is a key challenge for the medical community. Although women live longer than men, they face a higher burden of chronic diseases, such as cardiovascular diseases (CVDs) and disabilities. Endogenous estrogens appear to benefit cardiovascular health, and their marked decline at menopause is associated with increased cardiovascular risk; conversely, poor cardiovascular health may hasten menopause onset. Systemic menopause hormone therapy (MHT) begun early—ideally soon after symptom onset and at most within 10 years of the final menstrual period—alleviates climacteric symptoms and is associated with long‐term benefits. This joint position paper between the International Federation of Gynecology and Obstetrics (FIGO) and the World Heart Federation (WHF) aims at supporting both gynecologists and cardiologists in providing a tailored and evidence‐based counseling on systemic MHT use to women with increased CVD risk or established ischemic heart disease (IHD). Women with CVD risk factors require thorough risk stratification to tailor MHT type, dose, and route. For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. Women with established IHD may receive systemic MHT for symptom relief, provided risks and benefits are carefully reviewed. Transdermal low‐dose estrogen, alone or with micronized progesterone or dydrogesterone, is the best choice. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care. image

The Arquivos Brasileiros de Cardiologia (ABC Cardiol) is the most influential Brazilian scientific journal dedicated to the dissemination of research in cardiology and cardiovascular sciences. Founded in 1948 and published by the Brazilian Society of Cardiology (in Portuguese, SBC), it is over 70 years old and recognized as the highest-impact cardiology journal in Latin America. The ABC Cardiol is a monthly, bilingual publication, indexed in major international databases (PMC, PubMed Medline, Web of Science, Scopus, SciELO, Lilacs, DOAJ), adopts open [...] The Arquivos Brasileiros de Cardiologia (ABC Cardiol) is the most influential Brazilian scientific journal dedicated to the dissemination of research in cardiology and cardiovascular sciences. Founded in 1948 and published by the Brazilian Society of Cardiology (in Portuguese, SBC), it is over 70 years old and recognized as the highest-impact cardiology journal in Latin America. The ABC Cardiol is a monthly, bilingual publication, indexed in major international databases (PMC, PubMed Medline, Web of Science, Scopus, SciELO, Lilacs, DOAJ), adopts open

A inteligência artificial (IA) está transformando o processo científico em todos os seus estágios, tornando-se uma ferramenta inovadora, usada em âmbito global, que influencia a geração de pesquisa, o planejamento experimental, a análise de dados, a escrita e toda a complexa dinâmica de peer review e divulgação de resultados. À medida que toda a comunidade científica incorpora a IA como parte do processo de pesquisa para aprimoramento da eficiência, o desenvolvimento de regulação e algoritmos adequados para monitorar a qualidade, [...] A inteligência artificial (IA) está transformando o processo científico em todos os seus estágios, tornando-se uma ferramenta inovadora, usada em âmbito global, que influencia a geração de pesquisa, o planejamento experimental, a análise de dados, a escrita e toda a complexa dinâmica de peer review e divulgação de resultados. À medida que toda a comunidade científica incorpora a IA como parte do processo de pesquisa para aprimoramento da eficiência, o desenvolvimento de regulação e algoritmos adequados para monitorar a qualidade,

Artificial Intelligence (AI) is transforming the scientific process across all stages, making it an innovative tool, used globally, influencing research generation, experimental design, data analysis, writing, and all complex dynamics of peer review and dissemination of results. While the entire scientific community is incorporating AI as part of the research process to enhance efficiency, the development of regulations and adequate algorithms to monitor the quality, truthfulness, and integrity of data science is becoming a critical matter of discussion, regarding the [...] Artificial Intelligence (AI) is transforming the scientific process across all stages, making it an innovative tool, used globally, influencing research generation, experimental design, data analysis, writing, and all complex dynamics of peer review and dissemination of results. While the entire scientific community is incorporating AI as part of the research process to enhance efficiency, the development of regulations and adequate algorithms to monitor the quality, truthfulness, and integrity of data science is becoming a critical matter of discussion, regarding the